Category: Healthcare Industry

Alcon, Once Gem Worth Over $50 Billion, Weighs on Novartis

Alcon, the eye-care business that Novartis AG acquired for more than $50 billion, is now weighing on Europe’s second-largest drugmaker. After more than a year of efforts to turn around the business, the Swiss company on Wednesday said it was considering all options for the embattled division, including a spinoff or initial public offering.

Newron in Talks to License Schizophrenia Drug Tipped Blockbuster

Newron Pharmaceuticals SpA has held initial discussions with potential partners about licensing an experimental drug to treat schizophrenia, a mental health condition with no cure. “We see a good chance of a licensing deal in the second half of the year,” Chief Executive Officer Stefan Weber said in a telephone interview late on Tuesday.

ResMed: Cramer’s Top Takeaways

Jim Cramer takes a closer look at ResMed and its future as a medical-device maker focusing on sleep apnea and COPD. Did you miss last night’s “Mad Money” on CNBC ? If so, here are some of Jim Cramer’s top takeaways.

We’ve Changed Our Minds on Sanchez Energy

There’s been a lot of excitement regarding the recent OPEC agreement regarding the production of crude oil, in hopes of getting prices to stabilize and rise to higher levels. However, there is a lot of money to be made, and lost if not careful, in the energy sector that is largely unrelated to the now-impotent oil cartel.

EpiPen competitor to launch in February

A major competitor to EpiPen, the lifesaving allergy injection that has become the latest flashpoint in the debate over high drug prices, will launch on Valentine’s Day at a list price of $360 for a two-pack, the company KalA o announced on Thursday. For years, pharmaceutical company Mylan hiked the price on EpiPen — to $609 for a two-pack, enjoying a near monopoly on the growing allergy injection market.

5 Expensive Drugs That Could End Up in Trump’s Crosshairs

Donald Trump’s taking aim at drug companies that have increasingly found themselves in the hot seat because of sky-high drug price increases in the past. Last week, Trump likened the industry’s history of price hikes as akin to “getting away with murder,” and he hinted that significant changes to how government programs pay for medicine are afoot.

Here’s Why Alnylam Pharmaceuticals Plunged 59.8% in 2016

That was a far worse decline than the 19% loss by the biotech sector, in general, as measured by the iShares Nasdaq Biotechnology ETF While Alnylam’s share price was weak through the first nine months of the year, investors can mostly chalk that up to the general sell-off in biotech. However, the company’s stock was decimated in October after the company reported a major clinical setback.

Why Regeneron Pharmaceuticals, Sears Holdings, and Shake Shack Slumped Today

Friday was another record day for the stock market, with the Dow climbing above 19,999 without quite making it the final point higher to 20,000 before falling back toward the end of the day. A mixed jobs report seemed to give investors the perfect balance between economic strength and weakness, and market sentiment remained positive to frustrate those who had anticipated a quick pullback from the post-election rally once 2017 began.

Carlyle Said Exploring Sale of Vitamin-Maker Nature’s Bounty

Carlyle Group LP is exploring a sale of nutritional-supplements maker Nature’s Bounty Co., whose brands include “MET-Rx” and “Pure Protein,” people with knowledge of the matter said. The private equity firm has held talks with potential advisers about selling the U.S. company, formerly known as NBTY Inc., according to the people.

5 Stocks Setting Up for Big Breakouts

Trading stocks that trigger major breakouts can lead to massive profits. Once a stock trends to a new high, or takes out a prior overhead resistance point , it’s free to find new buyers and momentum players which can ultimately push the stock significantly higher.

Daily Dividend Report: ENB, PBA, CNP, COG, COO, SKT

Enbridge declared a quarterly dividend of $0.583 per common share, payable on March 1, 2017 to shareholders of record on February 15, 2017. The declared dividend represents a 10 percent increase from the prior quarterly rate and the twenty-second consecutive year in which the Company has increased its common share dividend.

Carlyle Said to Explore Sale of Vitamin Maker Nature’s Bounty

Carlyle Group LP is exploring a sale of nutritional-supplements maker Nature’s Bounty Co., whose brands include “MET-Rx” and “Pure Protein,” people with knowledge of the matter said. The private equity firm has held talks with potential advisers about selling the U.S. company, formerly known as NBTY Inc., according to the people.

Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales

Years before becoming a top cancer specialist, Eric Winer used to save money on his own medical care by talking U.S. pharmacists into giving him expired treatments for free. Winer, who has a bleeding disorder known as hemophilia, knew the drugs would still work for a brief time after the official use-by date.

European Stocks Open Lower as Investors Prep for U.S. Jobs Report

European stocks opened lower Friday as investors adopted a defensive stance ahead of key U.S. employment data amid a pullback in the dollar and increasing questions over the recent ‘Trump Rally’. The region-wide Stoxx 600 index, the broadest measure of European shares, slipped 0.2% by 08:30 GMT as benchmark indices drifted modestly lower across the board.

Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales

Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment. U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron Thursday to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.

Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales

Amgen Inc. won a court ruling blocking rivals Sanofi and Regeneron Pharmaceuticals Inc. from selling their cholesterol-lowering drug Praluent in the U.S. because it infringes Amgen’s patents covering a rival treatment. U.S. District Judge Sue Robinson in Delaware ordered Sanofi and Regeneron to halt Praluent sales for 12 years because the drug infringes patents on Amgen’s Repatha medication.

Why Encana, Acadia Pharmaceuticals, and Tenet Healthcare Jumped Today

The stock market continued to perform well on Wednesday, sending the S&P 500 to within a point of a new all-time record closing high. The Dow remained stubbornly below 20,000, but major market benchmarks posted gains of around half a percent as the latest release of minutes from the Federal Reserve’s Open Market Committee meeting didn’t raise any alarms or reveal any big surprises from monetary policymakers.

The reasons we don’t study gun violence the same way we study infections

Three decades ago, a pair of researchers wrote in one of the country’s leading medical journals about a common cause of death and injury in the United States that received very little federal funding. “A thorough review of research awards for 1983 failed to identify a single research project on the topic of firearm injuries,” the authors wrote after scouring a database of the research funded by the National Institutes of Health.

The reasons we don’t study gun violence the same way we study infections

Three decades ago, a pair of researchers wrote in one of the country’s leading medical journals about a common cause of death and injury in the United States that received very little federal funding. “A thorough review of research awards for 1983 failed to identify a single research project on the topic of firearm injuries,” the authors wrote after scouring a database of the research funded by the National Institutes of Health.

Why ImmunoGen, Inc. Shares Rocketed Higher by 29%

Unfortunately, the reason for ImmunoGen’s surge higher remains a bit of a mystery. The closest thing to tangible news for ImmunoGen that would have the potential to move the company’s stock was a press release this past Wednesday, Dec. 28. The press release was a needed feather in the cap for lead drug candidate mirvetuximab soravtansine .